3. Results
ADVERSE EVENTS
We included 15 patients who met our inclusion criteria. The demographic characteristics of the cohort are shown in In the first month of treatment, the global response was 26.6% (In the third month of treatment, only 13 patients continued the treatment. The global response was 30.8% (At six months of treatment, only seven patients continued the treatment. The global response was 57.1% (In the twelfth month of treatment, only four patients continued the treatment. The global response was 100%; three patients (75%) had a complete response, and one patient (15%) had a partial response.For the total treatment duration, the global response was 60% (nine patients); eight patients (53.3%) had a complete response, and one patient (6.7%) had a partial response. Six patients (40%) were considered to have undergone treatment failure.Adherence to the treatment was maintained during the follow-up. No adverse events related to the study treatment were noted throughout the duration of this study.For further analysis, we divided the cohort into two groups: (1) responders to treatment and (2) non-responders to treatment. In In the responder group, four patients maintained a complete response after treatment (55.5%), three patients maintained a partial response (33.3%), and one patient (11.1%) lost their response to the treatment.In 